Cat. Number:

Anti-ADK抗體XY-2778R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

widespread effects on the cardiovascular, nervous, respiratory, and immune systems and inhibitors of ADK could play an important pharmacological role in increasing intravascular adenosine concentrations and acting as antiinflammatory agents. The encoded protein does not present any sequence similarities to other well characterized mammalian nucleoside kinases. In contrast, 2 regions were identified with significant sequence identity to microbial ribokinase and fructokinases and a bacterial inosine/guanosine kinase. Thus, ADK is a structurally distinct mammalian nucleoside kinase that appears Anti-ADK抗體to be akin to sugar kinases of microbial origin. Animal studies have demonstrated that a deficiency of adenosine metabolism a powerful contributor to the development of neonatal hepatic steatosis, providing a model for the rapid development of postnatally lethal fatty liver.

Also known as:

Anti-ADK抗體Adenosine kinase; AK; 5033405D03Rik; AI255373; AI987814; MGC6593; 2310026J05Rik; Adenosine 5'-phosphotransferase; OTTHUMP00000019864; OTTHUMP00000019865; ADK_HUMAN; Adenosine kinase; AK; Full=Adenosine 5'-phosphotransferase.

Specificity:

Storage:

Shipped at 4℃, Anti-ADK抗體Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

Anti-ADK抗體WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.